Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Efficacy, Team × pembrolizumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 111 Squamous Cell Carcinoma of Head and Neck 57 Triple Negative Breast Neoplasms 50 Melanoma 50 Lung Neoplasms 48 Neoplasm Metastasis 46 Breast Neoplasms 39 Neoplasms 35 Colorectal Neoplasms 32 Carcinoma, Renal Cell 24 Head and Neck Neoplasms 23 Endometrial Neoplasms 23 Stomach Neoplasms 21 Ovarian Neoplasms 21 Uterine Cervical Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 19 Urinary Bladder Neoplasms 18 Carcinoma, Transitional Cell 16 Recurrence 15 Pancreatic Neoplasms 15 Esophageal Neoplasms 14 Carcinoma, Hepatocellular 13 Carcinoma, Squamous Cell 12 Glioblastoma 11 Carcinoma 11 Esophageal Squamous Cell Carcinoma 10 Brain Neoplasms 10 Sarcoma 9 Prostatic Neoplasms 9 Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡